Berardelli A, Formica A, Mercuri B, Abbruzzese G, Agnoli A, Agostino R, Caraceni T, Carella F, De Fazio G, De Grandis D
Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma.
Ital J Neurol Sci. 1993 Jun;14(5):361-7. doi: 10.1007/BF02340723.
In six Centers belonging to the Italian Movement Disorder Study Group, the efficacy of botulinum toxin treatment was evaluated in an open collaborative study in 251 patients with focal dystonia and hemifacial spasm. The percentage of functional improvement ranged from 66% to 81% in patients with blepharospasm, from 40% to 51% in patients with spasmodic torticollis and from 73% to 81% in those with hemifacial spasm. Good results were also obtained in patients with oromandibular dystonia, laryngeal dystonia and writer's cramp. Side effects were mild and transient. Local botulinum toxin injection is the first choice symptomatic treatment in focal dystonia and hemifacial spasm.
在隶属于意大利运动障碍研究小组的六个中心，通过一项开放性合作研究，对251例局限性肌张力障碍和半面痉挛患者的肉毒杆菌毒素治疗效果进行了评估。睑痉挛患者的功能改善百分比在66%至81%之间，痉挛性斜颈患者为40%至51%，半面痉挛患者为73%至81%。口下颌肌张力障碍、喉肌张力障碍和书写痉挛患者也取得了良好效果。副作用轻微且短暂。局部肉毒杆菌毒素注射是局限性肌张力障碍和半面痉挛的首选对症治疗方法。
